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Abstract
Background: Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide
polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk.
Method: We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than
1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624
controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association
Consortium (BCAC; http://bcac.ccge.medschl.cam.ac.uk/), and in 15,252 BRCA1 mutation carriers in the Consortium
of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify
independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer
Genome Atlas (TCGA) were used for functional annotation.
Results: Analysis of data from European descendants found evidence for four independent association signals at
12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06–1.12; P = 3 × 10-9),
rs805510 (OR = 1.08, 95 % CI = 1.04–1.12, P = 2 × 10-5), and rs1871152 (OR = 1.04, 95 % CI = 1.02–1.06; P = 2 × 10-4)
identified in the general populations, and rs113824616 (P = 7 × 10-5) identified in the meta-analysis of BCAC
ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated
with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African
descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin
interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the
strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression
of PTHLH and its nearby gene CCDC91 at P < 0.05.
Conclusion: This study identified four independent association signals at 12p11 and revealed potentially functional
variants, providing additional insights into the underlying biological mechanism(s) for the association observed
between variants at 12p11 and breast cancer risk.
Keywords: Fine-scale mapping, Genetic risk factor, PTHLH, CCDC91, Breast cancer, BRAC1 mutation carriers
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Background
A previous genome-wide association study (GWAS) iden-
tified a common single nucleotide polymorphism (SNP),
rs10771399 (termed the index SNP in this paper) at 12p11
to be associated with breast cancer risk in women of Euro-
pean descent [1]. This association, which did not vary by
estrogen receptor (ER) status, was one of the most signifi-
cant associations found for breast cancer risk in Breast
cancer 1 (BRCA1) mutation carriers so far, and the associ-
ation was predominantly found in carriers with ER-
negative (ER-(-)) breast cancer [2, 3]. This association was
also replicated in East Asian women [4]. The index SNP
lies in an approximately 300-kb linkage disequilibrium
(LD) block, containing one known breast cancer associ-
ated gene that encodes parathyroid hormone-like hor-
mone (PTHLH). This hormone has been shown to play a
role in breast tumor initiation, progression, and metastasis
in animal studies [5, 6] and was found to be associated
with prognosis in breast cancer patients [7]. The index
SNP, however, is located in a region with no evidence of
functional significance [8]. The underlying biologic mech-
anisms and functional variants that drive the observed as-
sociation have not yet been investigated. Furthermore, it is
possible that additional independent risk signals may be
present in the same region, as has been observed for other
susceptibility regions [9–11]. In order to identify add-
itional association signals at the12p11 locus with breast
cancer risk, understand the underlying mechanisms and
potential causal variants responsible for the association,
we conducted a large fine-scale mapping study including
data from 55,540 breast cancer cases and 51,168 controls
in the Breast Cancer Association Consortium (BCAC) and
15,252 BRCA1 mutation carriers in the Consortium of In-
vestigators of Modifiers of BRCA1/2 (CIMBA).
Methods
Study population
The BCAC included 40 studies of women of European
descent (48,155 cases and 43,612 controls), nine of Asian
descent (6269 cases and 6624 controls), and two of
African-American descent (1116 cases and 932 controls).
The CIMBA included 45 studies of women of European
descent (15,252 BRCA1 mutation carriers), of whom 7797
had been diagnosed with breast cancer. Details on the
study characteristics, participant characteristics and the
methodology used by the BCAC and CIMBA have been
published elsewhere [12–14]. Ethical approval of each
study was given by the local institutional review boards.
The full names of the institutional review boards that ap-
proved each study were listed in the Additional file 1.
SNP selection and genotyping
All SNPs within a 700-kb “fine mapping” interval at 12p11
(chr12: 27958733-28658733, hg19) were identified from
the 1000 Genomes Project (1000G) (http://browser.1000-
genomes.org) CEU (April 2010) [15] and Hapmap III [16]
(http://hapmap.ncbi.nlm.nih.gov/). The interval included
all SNPs in LD (r2 > 0.1) with the target SNP rs197593
(r2 = 0.95 with the index SNP rs10771399) [1]. Tagging
SNPs were selected to capture the remaining SNPs in
the fine-mapping region at r2 > 0.9. After quality con-
trol, genotypes for 441 SNPs were available for analysis.
To improve the coverage, imputation was performed
using data from the 1000G (March 2012) as the refer-
ence and the program IMPUTE2 [17] (https://math-
gen.stats.ox.ac.uk/impute/impute_v2.html). This was
done separately for women of European, East Asian,
and African descent and BRCA1 mutation carriers.
Using criteria of minor allele frequency (MAF) ≥2 %
and an imputation quality R2 > 0.3, genotype data were
generated for a total of 1634 SNPs for studies of European
women, 1360 for studies of East Asian women, 2508
for studies of African women in BCAC and 1646 for
studies of BRCA1 mutation carriers in CIMBA.
Statistical analysis
For BCAC studies, unconditional logistic regression
models were used to estimate allelic odds ratios (OR)
and their 95 % confidence intervals (CIs) of each of the
SNPs included in the study. Analyses were performed
separately for each ethnic group, and adjusted for study
and principal components (seven for European studies
and two each for Asian and African ancestry studies)
[12]. Additional adjustment for age (age at diagnosis for
cases and age at interview for controls) did not change
the estimates, and thus age was not adjusted for in the
main analyses. Tests of heterogeneity of the ORs across
studies were conducted using Cochran’s Q test. To
identify independent association signals, we performed
forward stepwise selection analyses with all SNPs associ-
ated with breast cancer risk at P < 0.0001 in BCAC
European descendants or at P < 0.005 for East Asian de-
scendants in the single-marker analysis. To reduce type
2 errors, we used a less stringent statistical significance
threshold because of the smaller sample size for East
Asian descendants than for European descendants in
this study. Pairwise SNP-SNP interactions were evalu-
ated using the likelihood ratio test for all SNPs selected
from the forward stepwise regression analysis. Stratified
analyses by ER status were performed, and the hetero-
geneity was assessed by case-only analysis. We estimated
haplotype frequencies using the haplo.stats package
under R with the expectation-maximum (EM) algorithm
[18] and estimated the haplotype-specific ORs for
women of European descent with adjustment for studies
and principal components as described above. To evalu-
ate whether the association varied by early-onset and
late-onset cancer, stratified analyses by age at cancer
diagnosis (≥45 or <45 years) were performed. The famil-
ial relative risk (FRR, λ) associated with independently
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associated variants in this locus was calculated using the
method described previously [19, 20].
For CIMBA studies, the associations between genetic
variants and breast cancer risk were evaluated using a 1-
degree of freedom (df) per allele trend test (P-trend), by
modeling the retrospective likelihood of the observed
genotypes conditional on breast cancer phenotypes [21].
To allow for the non-independence among related
individuals, an adjusted test statistic was used, which
took into account the correlation between study partici-
pants [22]. Per-allele hazard ratio (HR) estimates were
obtained by maximizing the retrospective likelihood. All
analyses were stratified by country of residence. To in-
crease the statistical power to detect independent signals
in BRCA1 mutation carriers, we conducted a meta-
analysis of the BCAC and CIMBA studies [23]. Because
approximately 80 % of breast tumors with known ER
status in BRCA1 mutation carriers were ER(-) [2], we
only included the ER(-) breast cancer cases for BCAC
studies. We combined the logarithm of the per-allele HR
estimated in BRCA1 mutation carriers and the logarithm
of the per-allele OR estimated in BCAC using a fixed-
effects model. We further determined whether there is
evidence for independent association signals through a
serial of conditional meta-analyses. We performed a
conditional analysis on the top variant identified in the
meta-analysis mentioned above in each consortium, and
carried out the meta-analysis on the conditional P value
for each variant to identify the most significant variant
after conditioning on the top variant in the whole
region. We continued to perform the conditional meta-
analyses until the most significant association found had
a P value >0.0001.
Functional annotation
We used the Encyclopedia of DNA Elements (EN-
CODE) chromatin states (chromHMM) annotation,
DNase I hypersensitive, transcription factor binding
sites, histone modifications of epigenetic markers
(H3K4Me1, H3K4Me3 and H3K27Ac) data from
ENCODE [24] (http://genome.ucsc.edu/ENCODE/) to
determine the likely regulatory elements. We used
chromatin interaction analysis by paired end tag (ChIA-
PET), genome conformation capture (Hi-C) data from
ENCODE and enhancer-promoter interaction data pre-
dicted by He et al. [25] to identify putative gene targets
in mammary cell lines (human mammary epithelial
cells (HMEC) and Michigan Cancer Foundation-7
(MCF7)). We used maps of enhancers as defined in
Corradin et al. [8] and Hnisz et al. [26] to identify the
locations of potential enhancers. We obtained RNA-seq
data from ENCODE, respectively, to evaluate the
expression of protein-coding genes in mammary cell
lines at this locus. We also used the same data in the
chronic myeloid leukemia cell line (K562) as a compari-
son if available.
To predict the most likely functional variants, we
mapped all candidates to the transcription factor binding
maps generated by ENCODE [24], based on the hypoth-
esis that causal variants alter the binding affinity of
transcription factors. We prioritized variants that were
located in binding sites of master transcription factors of
breast cancer and disrupted binding motif of transcrip-
tion factors. We also prioritized variants that were
located in active promoter regions in mammary cell
lines. Two publicly available tools, RegulomeDB [27]
(see http://regulome.stanford.edu/) and HaploReg V3
[28] (see http://www.broadinstitute.org/mammals/hap-
loreg/haploreg.php), were also used to evaluate those
candidate functional variants.
Expression quantitative trait loci (eQTL) analysis
The eQTL analyses in tumor tissues were performed as
previously described [29, 30]. Briefly, we downloaded
RNA-Seq V2, DNA methylation and SNP genotype data
of 1006 breast cancer tumor tissues from The Cancer
Genome Atlas (TCGA) data portal [26] (see http://can-
cergenome.nih.gov/). We log2-transformed the RNA-
Seq by expectation-maximization (RSEM) value of each
gene, and performed principal component adjustment
of gene expression data to remove potential batch
effects. Residual linear regression analysis was used to
detect eQTLs while adjusting for methylation and copy
number alterations (CNA), according to the approach
proposed by Li et al. [29].
The eQTL analyses in 135 tumor-adjacent normal
breast tissues were performed using data from the
Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) [31] as previously described
[32]. Briefly, gene expression levels were measured by
the Illumina HT12 v3 microarray platform. Genotyping
was performed using the Affymetrix SNP 6.0 array.
Imputation was performed using data from the 1000G
(CEU, March 2012) as the reference. Linear regression
was performed to evaluate the association between
genotypes and gene expression levels using the R (http://
www.r-project.org/) package Matrix eQTL [32].
Results
Association results among women of European ancestry
Of the 2075 SNPs evaluated, 833 were associated with
breast cancer risk in women of European descent at
P < 0.0001 (Fig. 1). Using forward stepwise selection,
we identified two SNPs that were independently associ-
ated with breast cancer risk with conditional P < 0.0001,
tagging two independent signals (Table 1, Fig. 1). The
index SNP is located in signal 2, approximately 30 kb
upstream of the PTHLH gene and was in strong LD with
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Fig. 1 (See legend on next page.)
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the lead SNP (rs805510) for this signal (r2 = 0.92). The
lead SNP in signal 1, rs7297051, is located approximately
50 kb upstream of the PTHLH gene, and was in moderate
LD with the index SNP (r2 = 0.42). The lead SNPs for
signals 1 and 2 were moderately correlated (r2 = 0.36).
After adjusting for the lead SNPs in signals 1 and 2,
we found evidence of the presence of a third independ-
ent association signal (lead SNP rs1871152; conditional
P = 2 × 10-4, Table 1, Fig. 1). Signal 3 lies approximately
60 kb upstream of another gene, coiled-coil domain con-
taining 91 (CCDC91). SNP rs1871152 was not correlated
with the lead SNP in signal 1 or signal 2 (r2 = 0.01
for rs7297051 and r2 = 0.03 for rs805510). All lead
SNPs for these three signals were associated with
breast cancer risk at P < 5 × 10-8 in single-marker ana-
lyses (rs7297051 OR = 0.88, P = 4 × 10-28; rs805510 OR
= 0.85, P = 10-25; rs1871152 OR = 0.94, P = 3 × 10-8). No
apparent heterogeneity in the ORs of the identified
SNPs across the 40 studies in BCAC was found (all
Pheterogeneity > 0.75). No statistically significant interac-
tions between any pair of these three lead SNPs were
found (all P > 0.05).
Using the lead SNP from each signal, rs805510,
rs7297051 and rs1871152, we identified seven haplotypes
with a frequency greater than 1 % (Table 2). The most
common haplotype (frequency 51 %), carrying the major
allele of each SNP, was used as the reference in the asso-
ciation analysis. The most statistically significant associ-
ation was observed for the haplotype carrying the minor
alleles at both signals 1 and 2 (TTA and TTG), while
less pronounced yet significant associations were ob-
served for individuals carrying the minor allele for signal
1 but not signal 2 (CTA and CTG), consistent with
results for the independent association signals from the
regression analyses. The evidence for signal 3 comes
largely from the observation that the CCG haplotype,
which carries the rare allele for signal 3 alone, was
associated with reduced risk. The haplotype carrying
only the minor allele in the lead SNP for signal 2 was
too rare to evaluate. Stratified analyses revealed no
evidence of any apparent heterogeneity in the associ-
ation of these haplotypes with breast cancer risk by
age at breast cancer diagnosis (age at diagnosis <45
vs ≥45 years).
The associations of the three SNPs did not vary appre-
ciably by ER status (Additional file 2: Table S3). In an at-
tempt to identify potential independent association
signals that might have been missed in the analysis
(See figure on previous page.)
Fig. 1 Genetic mapping and epigenetic landscape of the 12p11 locus (a). Regional association plot of the genotyped and imputed Illumina
iSelect genotyping array of the Collaborative Oncological Gene-environment Study (iCOGS) genotype data. Three independent signals were
identified, marked as signal 1, 2 and 3. b Functional annotations using data from the Encyclopedia of DNA Elements (ENCODE) project. From
top to bottom, the epigenetic signals evaluated include histone modifications, DNase clusters, transcription factor ChIP-seq clusters, and
ENCODE chromatin states (ChromHMM) in the ENCODE cell lines. The signals of different layered histone modifications from the same
ENCODE cell line are shown in the same color (the detailed color scheme for each ENCODE cell line is described in the UCSC genome
browser; http://genome.ucsc.edu). Red and orange in chromatin states represent active promoter and strong enhancer regions, respectively
(the detailed color scheme of the chromatin states was described in the previous study [45]). All tracks were generated by the UCSC genome
browser (hg 19). c Long-range chromatin interactions. From top to bottom, genome conformation capture (Hi-C), chromatin interaction
analysis by paired end tag (ChIA-PET) and RNA-Seq data from K562 cell lines, Hi-C and RNA-Seq from human mammary epithelial cells (HMEC),
ChIA-PET and RNA-Seq from MCF7 cell lines, gene annotations and single nucleotide polymorphism (SNP) annotations. Black lines represent
interactions with the promoter region (-1500/+500) of Parathyroid hormone-like hormone (PTHLH), and gray lines represent chromatin interaction that
did not involve the PTHLH promoter region. The value of the RNA-Seq analysis corresponds to the mean reads per million (RPM) value for PTHLH
from 65 K562, 4 HMEC and 19 MCF7 datasets, respectively. The annotation has been obtained through the Bioconductor annotation package
TxDb.Hsapiens.UCSC.hg19.knownGene. The Hi-C and ChIA-PET raw data, available in the Gene Expression Omnibus (GEO) [GSE63525.K56, GSE33664,
GSE39495], were processed using the GenomicRanges package. The tracks have been generated using ggplot2 and ggbio libraries in R
Table 1 Independent association signals identified for breast cancer risk in the 12p11 locus in women of European ancestry
Signal SNPs Position
(hg 19)
Alleles EAF LD
(r2)b
Univariate analysis Conditional analysis SNPs retained for
functional annotationePer-allele OR
(95 % CI)c
P-trend Per-allele OR
(95 % CI)d
P-trend
2 Indexa rs10771399 28155080 G*/A 0.12 - 0.85 (0.83–0.88) 5 × 10-25 - - -
1 rs7297051 28174817 T*/C 0.24 0.42 0.88 (0.86–0.90) 4 × 10-28 0.92 (0.89–0.94) 3 × 10-9 rs812020, chr12:28164044,
rs2619434, rs2590275
2 rs805510 28139846 T*/C 0.12 0.88 0.85 (0.82–0.88) 10-25 0.93 (0.89–0.96) 2 × 10-5 74 SNPsf
3 rs1871152 28379826 G*/A 0.31 0.04 0.94 (0.92–0.96) 3 × 10-8 0.96 (0.94–0.98) 2 × 10-4 376 SNPsg
*Effect alleles. aIdentified in the initial genome-wide association study conducted in women of European descent [1]. bLinkage disequilibrium (LD) with rs10771399
for women of European descent. cAdjusted for studies, and the top principal components and an additional principal component accounting for the Leuven
Multidisciplinary Breast Centre (LMBC) study. dIncluded all three variants, and was adjusted for studies, and the top eight principal components as well as an additional
principal component accounting for the LMBC study. eAssociated single nucleotide polymorphisms (SNPs) with a likelihood ratio >1/100 relative to the lead
SNP in each signal. fSee Table S2 in Additional file 5. gSee Table S2 in Additional file 5. EAF effect allele frequency in controls, OR odds ratio, CI confidence interval
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Table 2 Associations between common haplotypes derived using lead single nucleotide polymorphisms and breast cancer risk in women of European ancestry
Haplotype Overall breast cancer Breast cancer (age at diagnosis <45 years) Breast cancer (age at diagnosis ≥45 years) P heterogeneity
b
rs805510 - rs7297051-
rs1871152
Frequency OR (95 % CI)a P value Frequency OR (95 % CI)a P value Frequency OR (95 % CI)a P value
C-C-A 0.51 1.00 (Ref) Ref 0.52 1.00 (Ref) Ref 0.51 1.00 (Ref) Ref -
C-C-G 0.24 0.92 (0.89–0.95) 7 × 10-8 0.22 0.94 (0.89–1.00) 0.04 0.24 0.92 (0.89–0.95) 4 × 10-7 0.24
C-T-A 0.09 0.90 (0.87–0.95) 3 × 10-6 0.09 0.96 (0.89–1.03) 0.28 0.09 0.90 (0.86–0.94) 4 × 10-7 0.09
C-T-G 0.03 0.89 (0.82–0.96) 2 × 10-3 0.03 0.85 (0.73–0.98) 0.02 0.03 0.89 (0.82–0.96) 3 × 10-3 0.37
T-T-A 0.04 0.82 (0.77–0.88) 9 × 10-9 0.04 0.76 (0.67–0.87) 5 × 10-5 0.04 0.83 (0.76–0.85) 5 × 10-8 0.19
T-T-G 0.07 0.79 (0.76–0.83) 3 × 10-23 0.06 0.78 (0.71–0.85) 5 × 10-8 0.07 0.81 (0.77–0.85) 3 × 10-18 0.45
Rare 0.01 0.88 (0.79–0.99) 0.04 0.01 0.90 (0.72–1.13) 0.37 0.01 0.88 (0.78–0.99) 0.04 0.45
aAdjusted for studies and the top principal components. bP for heterogeneity between cases with age at diagnosis <45 years and ≥45 years. Ref reference
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described above that included all breast cancer cases
(Table 1), we conducted forward stepwise regression
analyses separately for ER(+) and ER(-) cases. For the
ER(+) breast cancer, the lead SNPs for signals 1 and 2
were identical to those found for all cases combined. For
signal 3, however, a different lead SNP (rs7959641) was
identified, which was moderately correlated with
rs1871152, the lead SNP identified in the overall analysis
(r2 = 0.28) (Additional file 2: Table S3). The lead SNP for
signal 3 in ER(-) cases is different from the SNP identi-
fied in all cases combined, but these two SNPs were
highly correlated (r2 = 0.86) (Additional file 2: Table S3).
Association results for BRCA1 mutation carriers of
European descent
Of the 2087 SNPs evaluated in the CIMBA among
BRCA1 mutation carriers of European descent, 234 were
associated with breast cancer risk at P < 0.0001. The
most significant association was found with rs113824616
(per-C allele HR 0.73, 95 % CI 0.64–0.82, P =1 × 10-7;
Table 3). The three lead SNPs identified in BCAC had
similar associations, although the association was statis-
tically significant at P < 0.05 in conditional analyses only
for the lead SNPs of signals 1 and 3 (rs7297051 and
rs1871152, respectively) (Additional file 3: Table S4).
Meta-analysis of data from BCAC ER(-) cases and
CIMBA showed that rs113824616 was associated with
breast cancer risk after adjusting for rs7297051 (condi-
tional P = 7 × 10-5, r2 with rs10773199 = 0.40; Table 3).
No additional independent signals were identified. We
defined the association signal represented by SNP
rs113824616 as signal 4.
Association results among women of East Asian ancestry
Of the 1801 SNPs evaluated, 118 were associated with
breast cancer risk in women of East Asian ancestry
(P < 0.005) (Fig. 1). The four lead SNPs in European
descendants had a similar association with breast
cancer risk in East Asian women, although the associ-
ation was statistically significant at P < 0.005 only for
the lead SNPs of signals 1 and 2 (rs7297051 and
rs805510, respectively) (Additional file 4: Table S5).
The MAFs for the lead SNPs of signals 1, 2 and 4 were
similar to those in Europeans, but the MAF for signal 3
(rs1871152) was markedly lower in East Asians. In con-
ditional regression analyses, only the association with
signal 1 was independently statistically significant, per-
haps due to the small sample size. The per-allele ORs
did not differ materially from those in Europeans in the
conditional analysis (data not shown).
The most significant association in Asians was
with SNP rs2737455 (MAF = 0.17, per-major (T) allele
OR = 1.16, 95 % CI 1.09–1.25, P = 10-5). Among women
of East Asian descent, this SNP was in high LD with
the two lead SNPs for signals 1 and 2 identified in pop-
ulations of European ancestry, rs7297051 (r2 = 0.67)
and rs805510 (r2 = 0.84). This variant was also associ-
ated with breast cancer in women of European descent
(per T-allele OR = 1.17, 95 % CI 1.14–1.21, P = 5 × 10-25).
No additional independent signal was found on stepwise
regression.
Association results for women of African ancestry
Of the 2949 SNPs evaluated in African descendants, 116
were statistically significantly associated with breast can-
cer risk at P < 0.05. The most significant association was
with rs10843021 (MAF = 0.38, per-C allele OR = 1.22,
95 % CI 1.08–1.39, P = 0.001), which is located 60 kb
downstream of the gene PTHLH. This SNP is not in LD
with any of the lead SNPs identified for women of
European or East Asian descent (all r2 < 0.02). There was
some evidence of association of this SNP with breast
cancer risk in women of European descent (P = 8 × 10-5)
but not in women of Asian descent (P = 0.23). None of
the lead SNPs identified for women of European or East
Asian descent were associated with breast cancer risk at
Table 3 Independent association signals in the meta-analysis of BCAC (ER-) and BRCA1 mutation carriers from CIMBA
SNPs Position
(hg 19)
Alleles EAF LD
(r2)§
Univariate analysis Conditional analysis
Per-allele effect (95 % CI)a P-trend Per-allele effect (95 % CI)b P-trend
Indexǂ rs10771399 28155080 G*/A 0.10 - 0.86 (0.80–0.91) 3 × 10-6 - -
Meta-analysis of ER-negative cancer (BCAC + CIMBA)
BCAC ER-
Signal 1 rs7297051 28174817 T*/C 0.24 0.42 0.87 (0.83–0.91) 3 × 10-10 0.89 (0.85–0.94) 1 × 10-5
Signal 4 rs113824616 28184905 C*/T 0.05 0.40 0.75 (0.67–0.84) 5 × 10-7 0.86 (0.76–0.98) 0.02
CIMBA BRCA1 mutation carriers
Signal 1 rs7297051 28174817 T*/C 0.23 0.37 0.89 (0.85–0.93) 3 × 10-7 0.94 (0.90–0.98) 0.003
Signal 4 rs113824616 28184905 C*/T 0.04 0.49 0.73 (0.64–0.82) 1 × 10-7 0.83 (0.74–0.93) 0.001
Effect for Breast Cancer Association Consortium (BCAC): odds ratio; effect for Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) cohort: hazard ratio.
*Effect alleles. aAdjusted for studies, and the top principal components. bIncluded both variants, and adjusted for studies and the top principal components.
SNPs single nucleotide polymorphisms, EAF effect allele frequency in the or (BCAC) controls, LD linkage disequilibrium, CI confidence interval, ER estrogen receptor. §represents
LD with the index SNP rs10771399. ǂrepresented the index SNP, Identified in the initial genome-wide association study conducted in women of European descent [1]
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P < 0.05 in African descendants, although the directions
of the associations were consistent and the effect sizes
did not differ significantly (Additional file 4: Table S5).
The MAF of the index SNP rs10771399 (MAF = 0.04)
was much lower in African descendants than that in
Asian and European descendants (P < 0.001).
Functional annotation
To identify putative causal variants, we used data from
European descendants to exclude any variants that had a
likelihood ratio <1/100 relative to the most significantly
associated SNP in each signal (33). Based on this thresh-
old, four variants in signal 1, 74 variants in signal 2, 376
variants in signal 3, and 2 variants in signal 4 were
retained as candidates for causal variants (Fig. 1a and
Additional file 5: Table S2).
Using data from ENCODE, we found that the histone
markers (H3K27Ac and H3K4Me3) were enriched in
each signal (Fig. 1b). Using both ChIA-PET chromatin
interaction data and Hi-C data from ENCODE, we
identified multiple and dense chromosomal interactions
of variants at signals 1 and 2 with the promoter region
of PTHLH in MCF7 cells (Fig. 1c). There was some
evidence of interaction of variants at signal 3 with
the promoter of PTHLH (Fig. 1c).
Using maps of predicted enhancer regions produced
by Hnisz et al. [26] and Corradin et al. [8], we found that
multiple candidate variants were located in enhancer
regions in mammary cell lines (Fig. 2). Using predicted
enhancer-promoter interaction data in HMEC and
MCF7 cell lines generated by He et al. [25] (Fig. 2), we
identified two interacting genes of these enhancers,
CCDC91 and PTHLH.
We next overlaid these candidate variants to the
transcription factor binding site maps generated from
ENCODE. We identified rs812020 within signal 1,
rs788463 and rs10843066 within signal 2, and rs10843110,
rs56318627 and rs11049453 within signal 3 to be the most
likely functional variants (Fig. 3a and b; Additional file 6:
Table S6). These SNPs were within or close to binding
sites of multiple breast cancer-related transcription fac-
tors. Furthermore, these SNPs were predicted to disrupt
Fig. 2 Enhancer-promoter interaction data at 12p11. From top to bottom, enhancer locations as defined by Corradin et al. [8] and Hnisz et al. [26]
are shown in human mammary epithelial cells (HMEC) cell lines. Enhancer-promoter (EP)-predicted interactions as defined by He et al. [25] are
shown in K562, MCF7 and HMEC cells. Gene annotations and single nucleotide polymorphism (SNP) annotations. Orange EP interactions are those
with the coiled-coil domain containing 91 (CCDC91) gene; blue EP are those with Parathyroid hormone-like hormone (PTHLH)
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the binding motifs recognized by transcription factors
(Fig. 3a and b), suggesting a regulatory role. For ex-
ample, in signal 1, rs812020 (per C-allele OR = 0.89,
95 % CI 0.87–0.91, P = 2 × 10-27) was annotated to a
region bound by multiple key transcription factors for
breast cancer, including GATA3 and FOXA1 (Fig. 3a
and b). This SNP is predicted to disrupt the binding
motif recognized by the transcription factor E2F3
and may change its binding affinity [32]. E2F3 has
been found to increase centrosome amplification in
mammary epithelial cells and regulate breast tumor
development and metastasis [33]. In signal 3, SNP
rs11049453 (per G-allele OR = 1.06, 95 % CI 1.04–1.08,
P = 9 × 10-8) was in the binding site of transcription
factors P300 and CTCF in MCF7 cell lines [31]
(Fig. 3). It was also predicted to disrupt the binding
motif of paired box (PAX) [33], which has been asso-
ciated with the progression of breast cancer [34, 35].
No functional significance of the candidate variants in
signal 4 was found.
Fig. 3 Putative functional variants and association of rs11049453 with gene expression in breast tumor tissues. a Epigenetic signals of five potential
functional variants. From top to bottom, lanes showing that those variants mapped to transcription factors predicted binding motifs, DNase I
hypersensitivity sites and transcription factor ChIP-Seq binding peaks in the Encyclopedia of DNA Elements (ENCODE) cell lines and MCF7. The
corresponding location of each variant is indicated by a dashed line. b Epigenetic landscape at the 12p11 locus for breast cancer risk. From top to
bottom, RefSeq genes (PTHLH and CCDC91), layered H3K4Me1, H3K4Me3 and H3K27Ac histone modifications and annotation using chromatin states
on the ENCODE cell lines. The signals of different layered histone modifications from the same ENCODE cell line are shown in the same color (the
detailed color scheme for each ENCODE cell line is described in the UCSC genome browser). Red and orange in the chromatin states represent the
active promoter and strong enhancer regions, respectively (the detailed color scheme of the chromatin states was described in the previous study
[45]). c rs11049453 and the expression of coiled-coil domain containing 91 (CCDC91) and parathyroid hormone-like hormone (PTHLH). The association of
the genotypes and the expression level of each gene was evaluated by residual linear regression [29]. bp base pairs, C/EBP CCAAT/enhancer-binding
protein, E2F3 E2F transcription factor 3, HNF1B HNF1 homeobox B, PPARG peroxisome proliferator-activated receptor gamma, PAX paired box
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To further explore the potential target genes, we
performed eQTL analysis in both breast tumor and nor-
mal tissues. Using data on tumor tissues from TCGA,
we found that rs10843110, rs56318627 and rs11049453
within signal 3 were associated with the expression of
PTHLH at P < 0.05 and CCDC91 at P < 0.10 (Additional
file 7: Table S7). Among these highly correlated SNPs,
the most significant association was found for rs11049453:
the risk allele G of rs11049453 was associated with
increased expression of PTHLH (P = 0.01) and decreased
expression of CCDC91 (P = 0.03, Fig. 3c). However,
we did not find any statistically significant association
for these six variants using data from adjacent normal
breast tissues from METABRIC (all P > 0.05).
Discussion
Through a fine-scale mapping study at 12p11, we iden-
tified four independent association signals for breast
cancer risk in women of European descent. It is of
interest that the fourth signal was identified only
through the meta-analysis of ER(-) breast cancer and
BRCA1 mutation carriers, suggesting that this signal
may be more specific to ER(-) cancers. The associations
of these signals were in general consistent in women of
European and East Asian descent.
Multiple genetic studies have confirmed that a locus
at 12p11 is associated with breast cancer risk [2, 4].
However, it remained unknown whether the observed
association was due to a single or multiple causal vari-
ants at this locus. In this study, we demonstrated that
there were at least four independent signals at 12p11,
three 100 kb upstream of the gene PTHLH (signals 1, 2
and 4), and one 60 kbp upstream from the gene
CCDC91 (signal 3), suggesting that there may be mul-
tiple causal variants and multiple underlying mecha-
nisms for the observed association at the 12p11 locus.
Furthermore, we identified multiple candidate causal
variants at each signal: four in signal 1, 74 in signal 2,
376 in signal 3 and 2 in signal 4. Using functional
genomic data from ENCODE, we observed that mul-
tiple candidate functional variants located in enhancer
regions, and identified PTHLH and CCDC91 as the
likely target genes for these enhancers. Using data on
transcription factor binding, we identified six putative
functional variants with strong evidence of regulation
of gene expression. Among these six variants, we ob-
served that the rs11049453 was significantly associated
with the expression of PTHLH and CCDC91. However,
we could not exclude the possibility that there were
other functional variants and other target genes at
this locus.
PTHLH encodes the protein PTHrP, which has intra-
crine, autocrine or paracrine action in most normal
tissues; its downstream effects include promotion of
growth and anti-apoptotic effects [36]. It is a cause of
humoral hypercalcemia of malignancy [37], and is
expressed in more than two thirds of breast tumor tissue
samples [7, 38]. It has been shown to affect the regula-
tion of tumor-related genes, and is thought to affect the
proliferation and migration of breast cancer cells [39].
PTHrP plays an important role in the formation of
osteolytic bone metastases in breast cancer through its
action on osteoblasts to increase RANK-ligand and
promote osteoclast formation [40]. It has been proposed
that PTHrP may promote breast cancer tumorigenesis;
however, previous studies had conflicting results [41].
Less is known about the function of the CCDC91 gene,
which is located approximately 232 kb from the PTHLH
gene. CCDC91 encodes a protein known as p56
accessory protein or GGA binding partner, which binds
proteins, and facilitates the transportation of secreted
proteins through the trans-Golgi network [42]. CCDC91
is also expressed in a variety of cancer cell lines includ-
ing MCF7 [43]. Using cBioPortal (http://www.cbioporta-
l.org/public-portal/), we found that both PTHLH and
CCDC91 genes were altered in breast tumors and that
there was a statistically significant co-occurrence of
alternations (including mutations and copy number
aberrations) in both genes (P for tendency towards
co-occurrence <0.001). Together with our findings,
these results suggest that there might be correlation
between these two genes and that alterations in both
genes might contribute concurrently to breast cancer
susceptibility. Future studies evaluating both genes
and their interrelationship are needed to elucidate the
underlying mechanism.
Functional annotation data suggested that the func-
tional variants underlying the observed association,
mainly those in signal 2, are located in enhancer
regions involved in the transcriptional regulation of
PTHLH and CCDC91 in the MCF7 and HMEC cells.
Moreover, we did not find similar functional evidence
for the same region in the K562 cells, which suggests
that the regulatory effects might be context-specific.
We identified multiple putative functional variants
associated with transcriptional factors that have been
found to be important for breast cancer, including
GATA3, FOXA1, C/EBP, P300 and STAT3, and
overlapped with binding motifs of transcriptional
factors, including E2F3, C/EBP, HNF1B, PPARG and
PAX. Despite strong evidence for altering the binding
of transcription factor and regulating gene transcrip-
tion, we found only one eQTL among these putative
functional variants, which lies in signal 3, suggesting
that the underlying functional variants might exert a
more subtle regulatory effect on gene expressions
than expected. Although we found strong genetic and
epigenetic evidence for potential functional variants in
Zeng et al. Breast Cancer Research  (2016) 18:64 Page 11 of 21
signals 1 and 2, we did not observe statistically significant
association between these variants and the expression
of PTHLH or CCDC91, or any other protein-coding
genes within a flanking region of 500 kb for each
variant. It is possible that the causal variants in these
two signals might be involved in regulating non-
coding genes or more distant genes. Future functional
studies that comprehensively investigate the regulatory
elements at these loci and their target genes will be
needed to elucidate the molecular mechanisms.
The top risk variants identified in women of Asian and
European ancestry were not associated with breast
cancer risk in African descendants. It is possible that
these top risk variants might not be correlated with the
causal variants in African descendants due to their
different LD structures. For example, the effect allele
frequencies (EAFs) for the index SNP rs10773199 and
the top risk variant rs805510 in African descendants
were 0.04 and 0.45, respectively, and the EAFs for
these two SNPs were similar in European descendants
(EAF = 0.12 for both SNPs) and in East Asian descen-
dants (EAF = 0.17 and 0.15, respectively), suggesting a
distinct LD structure at this locus in African descen-
dants. Similarly, the EAF for the SNP rs113824616 in
African descendants (EAF = 0.01) was substantially lower
than that in European descendants (EAF = 0.05). In
addition, the sample size for African descendants in-
cluded in this study was small and the power to detect
the association of these variants was low. A previous
fine-mapping study in African Americans with a larger
sample size (3016 cases/2745 controls) than our study
(1116 cases/932 controls) showed that rs10773199 is
marginally associated with breast cancer risk (OR =
0.84, P = 0.089) [44], suggesting that there might be an
association of the 12p11 locus with breast cancer risk
in African descendants. Studies with a large sample size
are needed to elucidate the association between this
locus and breast cancer risk in African descendants.
To date this is the largest and most comprehensive
fine-mapping study of the 12p11 region in relation to
breast cancer risk. By using densely genotyped data from
a very large number of cases and controls of European
descent, we derived highly reliable estimates of the
association between each common SNP and breast
cancer risk in women of European descent. The sample
size was relatively small for East Asian and African
descendants, and associations with risk of overall breast
cancer and molecular subtypes in these populations
should be further evaluated in future larger studies.
Conclusions
Through fine-mapping of the 12p11 locus, we identified
multiple independent association signals for breast
cancer risk. We estimate that the four independent
signals identified by this study explain approximately
1 % of the familial relative risk of breast cancer in
populations of European ancestry, more than doubling
the risk explained by the index SNP (0.4 %). Bioinfor-
matics analyses revealed that these signals are mapped
to enhancer regions that interact with the gene PTHLH
and CCDC91. We identified putative functional variants
that might contribute to the observed association.
Our findings also suggest a possible interrelation be-
tween PTHLH and CCDC91 in the etiology of breast
cancer. Our study has expanded the knowledge of
genetic risk associated with breast cancer at the
12p11 locus and provided clues for future functional
characterization.
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